Assessment of CAD-generated tumor volumes measured using MRI in breast cancers before and after neoadjuvant chemotherapy.

[1]  R. Reznek,et al.  CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. , 2000, The British journal of radiology.

[2]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[3]  A. Tardivon,et al.  Monitoring therapeutic efficacy in breast carcinomas , 2006, European Radiology.

[4]  L. Esserman,et al.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.

[5]  Yoshinobu Sato,et al.  Potential of Reduction in Total Tumor Volume Measured with 3D‐MRI as a Prognostic Factor for Locally‐Advanced Breast Cancer Patients Treated with Primary Chemotherapy , 2008, The breast journal.

[6]  Constance D Lehman,et al.  Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy. , 2005, Academic radiology.

[7]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[9]  Constance D. Lehman,et al.  Computer-Aided Detection Applied to Breast MRI: Assessment of CAD-Generated Enhancement and Tumor Sizes in Breast Cancers Before and After Neoadjuvant Chemotherapy1 , 2005 .

[10]  Mark J Ratain,et al.  Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Christian,et al.  Measuring response in solid tumors: unidimensional versus bidimensional measurement. , 1999, Journal of the National Cancer Institute.

[12]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[13]  M. Su.  Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy , 2009 .

[14]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[15]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[16]  Alfons G H Kessels,et al.  Intraobserver and Interobserver Agreement in Volumetric Assessment of Glioblastoma Multiforme Resection , 2010, Neurosurgery.

[17]  K. Marten,et al.  Inadequacy of manual measurements compared to automated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria , 2006, European Radiology.

[18]  C. Balu-Maestro,et al.  Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI , 2002, Breast Cancer Research and Treatment.

[19]  N M Hylton,et al.  Semi-automated analysis for MRI of breast tumors. , 1999, Studies in health technology and informatics.

[20]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[21]  武田 和奈.  MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy , 2012 .

[22]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.